Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)

(PA-489) Isatuximab Subcutaneous (Isa SC) via On-Body Injector (OBI) or Manual Injection for Relapsed/Refractory Multiple Myeloma (RRMM): Patient Experience from the Phase 2 IZALCO Study

(PA-462) Real-world (RW) Burden of Infection Among Triple-class–exposed (TCE) Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM)

(PA-465) Factors Influencing CAR T-Cell vs. Bispecific Antibody Preferences in Relapsed/Refractory Multiple Myeloma

(PA-466) Survival outcomes of KRD vs. IRD as Second-Line Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Retrospective Study with Propensity Score Matching

(PA-467) Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma After Bortezomib and Lenalidomide: A Real-World Study

(PA-469) Updated Results From the Phase 3 DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

(PA-470) Analysis of Infectious Risk in the Multiple Myeloma Patients Treated with Bispecific Antibodies. Real World experience

(PA-471) CYP3A4 Modulators Do Not Affect the Pharmacokinetics of Selinexor

(PA-473) Carfilzomib Use and Therapeutic Sequences in Patients with Relapsed/refractory Multiple Myeloma in France: An Analysis from a Large-scale Epidemiology of Multiple Myeloma (EmmY) Cohort

(PA-477) Validation of a Rule-Based Algorithm for Line-of-Therapy Assignment in Multiple Myeloma Using Simulated Data

(PA-480) BASECAMMP: An OBservational Retrospective Analysis of Treatment PatternS and Effectiveness of Standard of CAre for Multiple Myeloma Patients Exposed to Lenalidomide and a Proteasome Inhibitor

(PA-481) Socioeconomic Factors Affecting Health Equity in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

(PA-482) Understanding Specific Treatment Sequences in Multiple Myeloma Dependent on the Treatment Received in Second Line: Survey Data from 141 International Clinicians

(PA-484) Differences in Treatment Goals and Expectations Among Patients with Relapsed/refractory Multiple Myeloma Treated in Academic vs Community Settings

(PA-485) Real-world Healthcare Resource Utilization and Costs Among Triple-class–exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Patients With and Without Extramedullary Disease in the United States

(PA-486) RESCUE-LATAM Study: Real-world Evaluation of Salvage Combinations for Unmet needs in Expose and refractory multiple myeloma in LATAM Settings

(PA-487) Real-world Evidence of Melflufen Plus Dexamethasone in Heavily Pretreated Relapsed/refractory Multiple Myeloma Patients: Efficacy and Safety from a Single-center Experience

(PA-488) Efficacy and Safety of a China-developed BCMA-targeted CAR-T Therapy (Eque-cel) in Plasma Cell Leukemia: Real-world Multicenter Experience

(PA-490) Real-world (RW) Treatment (Tx) Patterns and Clinical Outcomes in Patients (pts) with Relapsed/refractory Multiple Myeloma (RRMM) with 2–4 Lines of Treatment: Data from the US Flatiron Database

(PA-491) Mezigdomide (MEZI) in Novel Combinations Effectively Reactivates Immune System in Patients with Relapsed/refractory Multiple Myeloma (RRMM) Including Those After T-cell–redirecting Therapies (TCRT)

(PA-492) Association Between Progression-Free Survival and Overall Survival Outcomes in Patients with Multiple Myeloma Previously Treated with Lenalidomide and an ANTI-CD38 Regimen: A Real-World Perspective

(PA-493) Real-World Use of Melflufen plus Dexametasone in Relapsed/Refractory Multiple Myeloma: A Retrospective Study from the Valencian Community and the Region of Murcia (Spain)

(PA-495) Outcomes After Second Autologous Hematopoietic Cell Transplant in Patients with Relapsed Multiple Myeloma in Latin America

(PA-496) Time Toxicity Associated with Selinexor-pomalidomide-dexamethasone versus Other Treatments for Relapsed/refractory Multiple Myeloma

(PA-500) Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment (Including Dialysis): Results From the Phase I DREAMM-12 Study

(PA-501) Characteristics and Outcomes of Multiple Myeloma Patients with Post-transplant Relapse: A Latin American Real-world Cohort Study

(PA-502) Characterization of Infections in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf)–Based Regimens From the DREAMM-7 and DREAMM-8 Trials

(PA-503) Trial in Progress: REALiTEC-2, an International Retrospective Study of Clinical Outcomes in Patients with Relapsed Refractory Multiple Myeloma Treated with Teclistamab in the Real World

(PA-505) Efficacy and Safety of Isatuximab Subcutaneous (SC) Plus Carfilzomib and Dexamethasone (Isa-Kd) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Results of the Phase 2 Study IZALCO

(PA-506) Isatuximab Subcutaneous via an On-body Injector Plus Pomalidomide-dexamethasone in Relapsed/refractory Multiple Myeloma: Subgroup Analysis by Prior Lines of Therapy from the Phase 3 IRAKLIA Trial

(PA-507) Patient Perspectives from the Phase 3 IRAKLIA Study of Isatuximab (Isa) Subcutaneous (SC) via On-body Injector (OBI) vs Isa Intravenous (IV) in Relapsed/refractory Multiple Myeloma (RRMM)

(PA-508) Infection Rate Profile of Etentamig Monotherapy in Patients with Relapsed/refractory Multiple Myeloma

(PA-511) Exploration of Efficacy for Frailty-adjusted Dose-reduced Pcd Regimen in Relapsed/refractory Multiple Myeloma

(PA-513) Clinical Features and Management of GPRC5D related AE in Chinese Relapsed/Refractory Multiple Myeloma Patients Treated with Talquetamab: MonumenTAL-1 China cohort experience

(PA-515) Real-world Characteristics and Outcomes of Patients with Relapsed or Refractory Multiple Myeloma Treated with Talquetamab: Early Results from eMMpower Consortium

(PA-524) Iberdomide Maintenance after Autologous Hematopoietic Cell Transplant for Patients who Previously Received Lenalidomide Maintenance

(PA-528) Real-World Management of Relapsed/Refractory Multiple Myeloma Following Early Anti-CD38 Exposure